Hospital
Verde Valley Medical Center
Verde Valley Medical Center was paid $26.43M by Medicaid between Jan 2018 and Dec 2024, across 246 billing codes. Its largest line is 99284, emergency room visit (serious) — 18% of everything it billed.
33Billing provider infoVERDE VALLEY MEDICAL CENTER
COTTONWOOD, AZ 86326
COTTONWOOD, AZ 86326
33aNPI1346291648assigned 05/12/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$26.43M
24GClaims620,081
24DCodes billed246
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Arizona
Rank by total paid#21 of 78
Median peer was paid$12.21M
This provider vs. median2.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 113,404 | $4.55M | |
| 2019 | 95,695 | $4.08M | |
| 2020 | 85,665 | $3.48M | |
| 2021 | 79,331 | $3.42M | |
| 2022 | 81,430 | $3.79M | |
| 2023 | 92,928 | $3.84M | |
| 2024incomplete | 71,628 | $3.27M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 18% | 20,889 | 18,432 | $4.79M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 16% | 20,007 | 18,318 | $4.25M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 14% | 5,536 | 5,154 | $3.61M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 10% | 8,687 | 7,730 | $2.66M |
| G0378 | Hospital observation service, per hour | 5.1% | 7,876 | 5,336 | $1.36M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 4.5% | 44,168 | 13,545 | $1.20M |
| 70450 | Computed tomography, head or brain; without contrast material | 2.4% | 4,972 | 4,483 | $636K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.1% | 1,417 | 1,315 | $546K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 2.1% | 2,645 | 2,541 | $543K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.8% | 1,421 | 1,326 | $477K |
| 72125 | Computed tomography, cervical spine; without contrast material | 1.7% | 1,443 | 1,330 | $448K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.5% | 4,272 | 4,051 | $388K |
234 more codes
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.2% | 1,519 | $313K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 23,189 | $261K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 8,323 | $238K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 823 | $226K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 336 | $214K |
| 72100 | <1% | 2,856 | $201K | |
| 76830 | Ultrasound, transvaginal | <1% | 1,528 | $183K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 3,652 | $174K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 337 | $153K |
| 73564 | <1% | 1,888 | $137K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 7,709 | $133K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,412 | $127K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 815 | $125K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 469 | $123K |
| 73110 | <1% | 2,488 | $115K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,369 | $112K |
| 72040 | <1% | 1,437 | $110K | |
| 73610 | <1% | 2,491 | $105K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,947 | $102K |
| 73030 | <1% | 3,049 | $101K | |
| 80053 | Comprehensive metabolic panel | <1% | 28,264 | $101K |
| 59025 | Fetal non-stress test | <1% | 1,186 | $99K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 6,422 | $95K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 246 | $94K |
| 73562 | <1% | 3,007 | $88K | |
| 73630 | <1% | 2,939 | $87K | |
| 73130 | <1% | 2,575 | $80K | |
| 97161 | <1% | 4,206 | $78K | |
| 94726 | <1% | 205 | $77K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 480 | $74K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 914 | $73K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 441 | $72K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,997 | $65K |
| 76536 | <1% | 762 | $60K | |
| 73502 | <1% | 1,748 | $59K | |
| 97597 | <1% | 834 | $58K | |
| 74018 | <1% | 1,538 | $55K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 67 | $52K |
| 77080 | <1% | 979 | $52K | |
| 71250 | <1% | 519 | $48K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 13,631 | $44K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 7,495 | $38K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 3,573 | $37K |
| 76642 | <1% | 531 | $36K | |
| 72072 | <1% | 516 | $34K | |
| 93971 | <1% | 1,108 | $34K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,685 | $34K |
| 76770 | <1% | 411 | $28K | |
| 97162 | <1% | 1,698 | $26K | |
| 95811 | <1% | 39 | $25K | |
| 76641 | <1% | 177 | $23K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 5,362 | $22K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 2,953 | $21K |
| 73221 | <1% | 127 | $21K | |
| 72141 | <1% | 132 | $21K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 4,968 | $18K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 9,559 | $16K |
| 71045 | Radiologic examination, chest; single view | <1% | 8,109 | $16K |
| 97165 | <1% | 658 | $15K | |
| 73080 | <1% | 418 | $13K | |
| 70486 | <1% | 199 | $13K | |
| 93017 | <1% | 252 | $12K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,151 | $11K |
| 12001 | <1% | 93 | $11K | |
| 87641 | <1% | 614 | $11K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 13,520 | $8K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,770 | $7K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,498 | $7K |
| 76937 | <1% | 59 | $7K | |
| 77336 | <1% | 47 | $6K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 444 | $6K |
| 73140 | <1% | 215 | $6K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 3,162 | $6K |
| 99460 | <1% | 82 | $5K | |
| 87186 | <1% | 1,450 | $5K | |
| 73090 | <1% | 206 | $5K | |
| 97116 | <1% | 1,328 | $5K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 236 | $5K |
| 97750 | <1% | 349 | $5K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 177 | $5K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 330 | $4K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 5,203 | $4K |
| 97166 | <1% | 70 | $4K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 100 | $4K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 57 | $4K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 622 | $4K |
| 97032 | <1% | 1,555 | $4K | |
| J3490 | Unclassified drugs | <1% | 3,701 | $4K |
| 87040 | <1% | 1,974 | $4K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 33,053 | $4K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,587 | $4K |
| G0379 | Direct admission of patient for hospital observation care | <1% | 1,636 | $4K |
| 72110 | <1% | 42 | $4K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 9,667 | $4K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 944 | $3K |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 51 | $3K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 5,669 | $3K |
| 94060 | <1% | 187 | $3K | |
| 93880 | <1% | 41 | $3K | |
| 90715 | <1% | 740 | $3K | |
| 73590 | <1% | 110 | $3K | |
| 70496 | <1% | 14 | $2K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,333 | $2K |
| 70498 | <1% | 42 | $2K | |
| 87631 | <1% | 688 | $2K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 216 | $2K |
| 72131 | <1% | 26 | $2K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 4,116 | $2K |
| 87077 | <1% | 1,450 | $2K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 5,754 | $2K |
| 76801 | <1% | 66 | $2K | |
| 83880 | <1% | 1,997 | $2K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 151 | $1K |
| 87088 | <1% | 5,249 | $1K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 37,532 | $1K |
| J1815 | Injection, insulin, per 5 units | <1% | 18 | $1K |
| 73700 | <1% | 14 | $1K | |
| 80329 | <1% | 2,117 | $1K | |
| 95812 | <1% | 14 | $1K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 276 | $1K |
| 97035 | <1% | 422 | $1K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 4,163 | $1K |
| 74019 | <1% | 39 | $1K | |
| 84484 | <1% | 7,727 | $1K | |
| 77066 | Tomosynthesis, mammo | <1% | 305 | $1K |
| 83690 | <1% | 8,091 | $838.30 | |
| 71271 | <1% | 12 | $824.29 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,774 | $774.51 |
| 83605 | <1% | 6,063 | $767.05 | |
| 81025 | <1% | 4,943 | $746.77 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,164 | $732.28 |
| 85610 | <1% | 7,201 | $725.89 | |
| 86141 | <1% | 209 | $598.97 | |
| 86140 | <1% | 464 | $597.23 | |
| 84703 | <1% | 2,576 | $554.60 | |
| 81001 | <1% | 10,620 | $537.54 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 416 | $527.67 |
| 83735 | <1% | 5,137 | $519.76 | |
| 94729 | <1% | 230 | $475.20 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 504 | $473.42 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 6,238 | $434.67 |
| 85379 | <1% | 1,640 | $433.94 | |
| 77065 | Tomosynthesis, mammo | <1% | 55 | $421.92 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 7,032 | $387.17 |
| 85730 | <1% | 2,109 | $382.60 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,676 | $365.45 |
| 84702 | <1% | 551 | $324.99 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 28 | $305.00 |
| 82803 | <1% | 570 | $262.36 | |
| 87070 | <1% | 254 | $244.82 | |
| 74022 | <1% | 12 | $242.86 | |
| 96376 | <1% | 2,689 | $226.81 | |
| 80061 | Lipid panel | <1% | 300 | $216.01 |
| A9270 | Non-covered item or service | <1% | 2,916 | $210.23 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 8,229 | $204.67 |
| 88342 | <1% | 98 | $187.21 | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 244 | $154.89 |
| 82140 | <1% | 31 | $151.03 | |
| 86900 | <1% | 1,035 | $139.09 | |
| 80320 | <1% | 3,997 | $137.69 | |
| 81003 | <1% | 5,186 | $137.68 | |
| 97803 | <1% | 13 | $109.65 | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 16 | $92.27 |
| 82962 | <1% | 3,984 | $89.39 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,395 | $87.98 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 891 | $81.27 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,545 | $80.48 |
| 86901 | <1% | 763 | $70.75 | |
| 82550 | <1% | 1,216 | $65.31 | |
| 82150 | <1% | 237 | $58.18 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,798 | $56.82 |
| 84100 | <1% | 1,747 | $56.17 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 94 | $54.09 |
| 86850 | <1% | 462 | $53.23 | |
| 96367 | <1% | 43 | $49.42 | |
| 82776 | <1% | 12 | $47.80 | |
| 97016 | <1% | 5,254 | $46.56 | |
| 87581 | <1% | 586 | $45.75 | |
| 87486 | <1% | 586 | $45.75 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,079 | $45.33 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 912 | $25.00 |
| 84145 | <1% | 148 | $17.77 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 296 | $12.82 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 68 | $6.31 |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 92 | $5.00 |
| 87205 | <1% | 262 | $4.01 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 351 | $2.48 |
| 85652 | <1% | 472 | $1.73 | |
| S0028 | Injection, famotidine, 20 mg | <1% | 305 | $0.95 |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 2,709 | $0.36 |
| G8985 | Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 150 | $0.02 |
| 94760 | 0% | 1,448 | $0.00 | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | 0% | 877 | $0.00 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 104 | $0.00 |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 28 | $0.00 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 146 | $0.00 |
| C9399 | Unclassified drugs or biologicals | 0% | 95 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 80 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 147 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 83 | $0.00 |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 61 | $0.00 |
| 88738 | 0% | 71 | $0.00 | |
| 97014 | 0% | 30 | $0.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 34 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 65 | $0.00 |
| G8982 | Changing & maintaining body position functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 42 | $0.00 |
| 85027 | 0% | 50 | $0.00 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 57 | $0.00 |
| G8981 | Changing & maintaining body position functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 17 | $0.00 |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | 0% | 15 | $0.00 |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 14 | $0.00 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 0% | 20 | $0.00 |
| J3535 | Drug administered through a metered dose inhaler | 0% | 13 | $0.00 |
| 88304 | 0% | 12 | $0.00 | |
| G8991 | Other physical or occupational therapy primary functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 15 | $0.00 |
| 82270 | 0% | 27 | $0.00 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 3,200 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 203 | $0.00 |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | 0% | 84 | $0.00 |
| 84439 | 0% | 64 | $0.00 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 360 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 618 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 493 | $0.00 |
| 94799 | 0% | 36 | $0.00 | |
| S4991 | Nicotine patches, non-legend | 0% | 15 | $0.00 |
| 77061 | 0% | 12 | $0.00 | |
| 77062 | 0% | 38 | $0.00 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 16 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 47 | $0.00 |
| 29125 | 0% | 14 | $0.00 | |
| G8984 | Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 63 | $0.00 |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | 0% | 40 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 35 | $0.00 |
| 76376 | 0% | 43 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCOFIELD, ROBERT (CHIEF OPERATING OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Flagstaff Medical Center | Flagstaff, AZ | $63.33M |
| Flagstaff Medical Center | Flagstaff, AZ | $46.22M |
| Flagstaff Medical Center | Flagstaff, AZ | $37.58M |
| Northern Arizona Healthcare Corporation | Flagstaff, AZ | $11.37M |
| Northern Arizona Healthcare Corporation | Flagstaff, AZ | $6.03M |
| Verde Valley Medical Center | Sedona, AZ | $1.12M |
| Northern Arizona Healthcare Orthopedic Surgery Center, LLC | Flagstaff, AZ | $354K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.